Raras
Buscar doenças, sintomas, genes...
Amiloidose cutânea
ORPHA:137807CID-11 · 5D00.0DOENÇA RARA

A amiloidose cutânea é um grupo de doenças de pele que, ao serem examinadas ao microscópio, mostram um acúmulo de depósitos de uma substância chamada amiloide fora das células da derme (a camada intermediária da pele). Entre as formas raras estão o líquen amiloide, o distúrbio pigmentar reticulado ligado ao cromossomo X, a amiloidose nodular cutânea localizada primária e a amiloidose macular.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A amiloidose cutânea é um grupo de doenças de pele que, ao serem examinadas ao microscópio, mostram um acúmulo de depósitos de uma substância chamada amiloide fora das células da derme (a camada intermediária da pele). Entre as formas raras estão o líquen amiloide, o distúrbio pigmentar reticulado ligado ao cromossomo X, a amiloidose nodular cutânea localizada primária e a amiloidose macular.

Pesquisas ativas
2 ensaios
5 total registrados no ClinicalTrials.gov
Publicações científicas
181 artigos
Último publicado: 2026 Feb

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
9.8
Taiwan, Province of China
Início
All ages
🏥
SUS: Cobertura mínimaScore: 20%
1 medicamentos CEAF
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Características mais comuns

Hiperpigmentação generalizada
Fotossensibilidade cutânea
Mácula hiperpigmentada
Descamação da pele
Liquenificação
Prurido
10sintomas
Sem dados (10)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 10 características clínicas mais associadas, ordenadas por frequência.

Hiperpigmentação generalizadaGeneralized hyperpigmentation
Fotossensibilidade cutâneaCutaneous photosensitivity
Mácula hiperpigmentadaHypermelanotic macule
Descamação da peleScaling skin
LiquenificaçãoLichenification

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico181PubMed
Últimos 10 anos75publicações
Pico201710 papers
Linha do tempo
2026Hoje · 2026🧪 1998Primeiro ensaio clínico📈 2017Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Not applicable.

IL31RAInterleukin-31 receptor subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Associates with OSMR to form the interleukin-31 receptor which activates STAT3 and to a lower extent STAT1 and STAT5 (PubMed:11877449, PubMed:14504285, PubMed:15194700, PubMed:15627637). May function in skin immunity (PubMed:15184896). Mediates IL31-induced itch, probably in a manner dependent on cation channels TRPA1 and TRPV1 (By similarity). Positively regulates numbers and cycling status of immature subsets of myeloid progenitor cells in bone marrow in vivo and enhances myeloid progenitor ce

LOCALIZAÇÃO

Cell membranePresynaptic cell membraneCell projection, axon

VIAS BIOLÓGICAS (1)
IL-6-type cytokine receptor ligand interactions
MECANISMO DE DOENÇA

Amyloidosis, primary localized cutaneous, 2

A primary amyloidosis characterized by localized cutaneous amyloid deposition. This condition usually presents with itching (especially on the lower legs) and visible changes of skin hyperpigmentation and thickening that may be exacerbated by chronic scratching and rubbing. Primary localized cutaneous amyloidosis is often divided into macular and lichen subtypes although many affected individuals often show both variants coexisting. Lichen amyloidosis characteristically presents as a pruritic eruption of grouped hyperkeratotic papules with a predilection for the shins, calves, ankles and dorsa of feet and thighs. Papules may coalesce to form hyperkeratotic plaques that can resemble lichen planus, lichen simplex or nodular prurigo. Macular amyloidosis is characterized by small pigmented macules that may merge to produce macular hyperpigmentation, sometimes with a reticulate or rippled pattern. In macular and lichen amyloidosis, amyloid is deposited in the papillary dermis in association with grouped colloid bodies, thought to represent degenerate basal keratinocytes. The amyloid deposits probably reflect a combination of degenerate keratin filaments, serum amyloid P component, and deposition of immunoglobulins.

EXPRESSÃO TECIDUAL(Baixa expressão)
Aorta
1.9 TPM
Testículo
1.8 TPM
Fibroblastos
0.8 TPM
Skin Sun Exposed Lower leg
0.5 TPM
Skin Not Sun Exposed Suprapubic
0.5 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (2)
amyloidosis, primary localized cutaneous, 2familial primary localized cutaneous amyloidosis
HGNC:18969UniProt:Q8NI17
OSMROncostatin-M-specific receptor subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Associates with IL31RA to form the IL31 receptor. Binds IL31 to activate STAT3 and possibly STAT1 and STAT5. Capable of transducing OSM-specific signaling events

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (1)
IL-6-type cytokine receptor ligand interactions
MECANISMO DE DOENÇA

Amyloidosis, primary localized cutaneous, 1

A primary amyloidosis characterized by localized cutaneous amyloid deposition. This condition usually presents with itching (especially on the lower legs) and visible changes of skin hyperpigmentation and thickening that may be exacerbated by chronic scratching and rubbing. Primary localized cutaneous amyloidosis is often divided into macular and lichen subtypes although many affected individuals often show both variants coexisting. Lichen amyloidosis characteristically presents as a pruritic eruption of grouped hyperkeratotic papules with a predilection for the shins, calves, ankles and dorsa of feet and thighs. Papules may coalesce to form hyperkeratotic plaques that can resemble lichen planus, lichen simplex or nodular prurigo. Macular amyloidosis is characterized by small pigmented macules that may merge to produce macular hyperpigmentation, sometimes with a reticulate or rippled pattern. In macular and lichen amyloidosis, amyloid is deposited in the papillary dermis in association with grouped colloid bodies, thought to represent degenerate basal keratinocytes. The amyloid deposits probably reflect a combination of degenerate keratin filaments, serum amyloid P component, and deposition of immunoglobulins.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
117.0 TPM
Adipose Visceral Omentum
72.4 TPM
Pulmão
67.0 TPM
Artéria tibial
57.4 TPM
Aorta
55.9 TPM
OUTRAS DOENÇAS (2)
amyloidosis, primary localized cutaneous, 1familial primary localized cutaneous amyloidosis
HGNC:8507UniProt:Q99650
GPNMBTransmembrane glycoprotein NMBDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Could be a melanogenic enzyme

LOCALIZAÇÃO

Cell membraneMelanosome membraneEarly endosome membrane

VIAS BIOLÓGICAS (1)
PTK6 promotes HIF1A stabilization
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Ectocervix
316.2 TPM
Skin Not Sun Exposed Suprapubic
299.5 TPM
Cervix Endocervix
270.1 TPM
Skin Sun Exposed Lower leg
250.8 TPM
Aorta
177.0 TPM
OUTRAS DOENÇAS (2)
amyloidosis, primary localized cutaneous, 3amyloidosis cutis dyschromia
HGNC:4462UniProt:Q14956

Variantes genéticas (ClinVar)

96 variantes patogênicas registradas no ClinVar.

🧬 GPNMB: GRCh37/hg19 7p22.3-14.3(chr7:158725-29918785)x3 ()
🧬 GPNMB: GRCh37/hg19 7p21.1-15.3(chr7:18093509-25363633)x1 ()
🧬 GPNMB: GRCh37/hg19 7p21.2-15.2(chr7:16417575-27541028)x3 ()
🧬 GPNMB: NM_002510.3(GPNMB):c.1019-316G>A ()
🧬 GPNMB: NM_002510.3(GPNMB):c.701-1G>T ()
Ver todas no ClinVar

Vias biológicas (Reactome)

2 vias biológicas associadas aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 3 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Amiloidose cutânea

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

5 ensaios clínicos encontrados, 2 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
75 papers (10 anos)
#1

Symptomatic Vulvar Primary Cutaneous Amyloidosis Associated With Low-Risk HPV: A Case Report.

Clinical case reports2026 Feb

Primary localized cutaneous amyloidosis (PCLA) of the vulva is an infrequent diagnosis. Its clinical presentation may mimic neoplastic or inflammatory lesions and could even be associated with human papillomavirus (HPV) of low or high oncogenic risk, making accurate diagnosis and exclusion of systemic involvement essential. A 73-year-old woman presented with a flat, macular, solitary vulvar lesion. Histologic evaluation revealed amyloid deposits in the papillary dermis, confirmed by Congo red staining and apple-green birefringence. HPV genotyping identified type 40, a low-risk genotype, with no evidence of intraepithelial neoplasia. The diagnosis of systemic amyloidosis was ruled out by a multidisciplinary team evaluation. A complete local excision was performed. After 33 months of follow-up, the patient remains in remission. This case highlights the importance of including PCLA in the differential diagnosis of vulvar lesions and suggests a potential role of HPV as a possible trigger for vulvar localized amyloidogenesis.

#2

Cutaneous Amyloidosis: An Updated Approach Focusing on Macular Amyloidosis.

Dermatology (Basel, Switzerland)2026 Jan 13

Amyloidosis is formed following deposition of protein aggregates and is classified by systemic or cutaneous deposition. These aggregates can be distributed in different organs such as the heart, liver, lungs, kidneys, and skin. Primary cutaneous amyloidosis has been classified into three groups: macular, lichen, and nodular, the former two being one often overlapping process, and the latter a localized plasma dyscrasia with a small risk of representing a systemic disease. Historically, cutaneous amyloidosis has been misdiagnosed, and most treatment regimens have been ineffective or only provide supportive management, such as decreasing pruritus. The current standard of care, high-potency corticosteroids, can provide symptomatic relief. Newer therapies may decrease amyloid deposition and progression of disease.

#3

Dermatological Manifestations of Amyloid Light-Chain (AL) Amyloidosis: A Case Report Highlighting Early Diagnosis and Treatment.

Cureus2025 Dec

This case report describes a 52-year-old man who presented with gradually progressive dark cutaneous discoloration over the upper trunk and periorbital region, accompanied by painless enlargement of the tongue, which initially interfered with speech and eating. Over the subsequent months, he experienced marked unintentional weight loss, persistent fatigue, and symptoms consistent with autonomic involvement, including postural dizziness and altered bowel habits. Clinical examination revealed waxy skin changes and macroglossia. Laboratory evaluation demonstrated a monoclonal light-chain abnormality, and additional testing identified abnormal serum protein bands and Bence-Jones protein in urine. Cross-sectional imaging showed hepatosplenomegaly without focal lesions, and biopsy of the abdominal fat pad confirmed amyloid deposition. Based on the constellation of clinical, laboratory, imaging, and histopathologic findings, a diagnosis of systemic amyloid light-chain (AL) amyloidosis was established. The patient was initiated on bortezomib and dexamethasone chemotherapy targeting abnormal light-chain production, following which he exhibited progressive improvement in dermatologic changes, reduction in tongue size, improved energy levels, and stabilization of autonomic symptoms. This case underscores an atypical dermatologic onset of systemic AL amyloidosis, in which skin and tongue abnormalities preceded other systemic manifestations, enabling timely diagnosis and intervention.

#4

[Tapping with plum-blossom needle combined with sulfur ointment and local irradiation for primary cutaneous amyloidosis: a case report].

Zhongguo zhen jiu = Chinese acupuncture &amp; moxibustion2025 Dec 12

The paper reports one case of primary cutaneous amyloidosis (PCA) treated by tapping with plum-blossom needle combined with sulfur ointment and local irradiation. PCA in this case was manifested as generalized erythema, papules, plaques, lichenification, and severe pruritus. In treatment, tapping with plum-blossom needle was delivered at typical lesions to induce local congestion, redness, and minimal bleeding. After cleaned with sterile gauze for 10 s, 25% sulfur ointment was evenly applied, followed by local irradiation with a TDP lamp for 15 min. This session was repeated twice a week. In 1 month of treatment, the lesions turned flat and the skin was soft as the normal, with pigmentation and mild pruritus left. In 3 months of follow-up, no papules recurred, and mild pruritus presented occasionally. 报道1例采用梅花针吹烘疗法治疗原发性皮肤淀粉样变的情况。本例患者表现为泛发性红斑、丘疹、斑块,苔藓样变,有剧烈瘙痒。治疗选取皮损典型部位,使用梅花针叩刺,至皮损充血、发红、轻微渗血为度,用无菌纱布块轻按10 s,擦净渗血,继用25%硫乳膏均匀涂抹于皮疹处,配合特定电磁波治疗仪(TDP)局部照射15 min,每周2次。治疗1个月后皮疹变平,皮肤质地柔软近似正常皮肤,遗留色素沉着,瘙痒轻微;随访3个月,皮疹未见复发,偶有轻微瘙痒。.

#5

Treatment of primary cutaneous amyloidosis with tofacitinib: preliminary observations from a single-arm clinical trial.

Clinical and experimental dermatology2025 Dec 23

Primary cutaneous amyloidosis (PCA) lacks consensus-based therapeutic guidelines, with conventional modalities demonstrating suboptimal clinical responses. To assess the efficacy and safety profile of oral tofacitinib, a Janus kinase 1/3 inhibitor, in PCA management. This single-centre, open-label, single-arm prospective interventional study enrolled 20 patients with PCA receiving tofacitinib 5 mg twice daily. Demographic parameters, disease characteristics [measured using the pruritus numeric rating scale (p-NRS), Dermatology Life Quality Index (DLQI) and Lesion Severity (LS) scores], and adverse events were systematically recorded at baseline and weeks 2, 6 and 10 post-treatment. At week 10, significant reductions were observed across all endpoints: p-NRS from 6.9 (SD 2.9) to 0.4 (SD 0.6, P < 0.001); DLQI from 11.8 (SD 5.6) to 2.6 (SD 2.5, P < 0.001); and LS from 13.3 (SD 5.2) to 4.9 (SD 2.4, P < 0.001). Patients with lichen amyloidosis (8 of 15) and biphasic amyloidosis (3 of 3), but neither of the 2 patients with macular amyloidosis, achieved the primary efficacy threshold. Two treatment-emergent adverse events occurred; these were transient hepatobiliary enzyme elevations resolving with hepatoprotectants and one patient with a self-limiting upper respiratory infection. Tofacitinib demonstrates rapid antipruritic effects and sustained lesion clearance in PCA, with favourable tolerability. Study limitations, including the small sample size (n = 20), 10-week duration and uncontrolled design, which may limit generalizability, warrant phase III trials for validation.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC108 artigos no totalmostrando 74

2026

Symptomatic Vulvar Primary Cutaneous Amyloidosis Associated With Low-Risk HPV: A Case Report.

Clinical case reports
2025

Dermatological Manifestations of Amyloid Light-Chain (AL) Amyloidosis: A Case Report Highlighting Early Diagnosis and Treatment.

Cureus
2026

Cutaneous Amyloidosis: An Updated Approach Focusing on Macular Amyloidosis.

Dermatology (Basel, Switzerland)
2025

[Tapping with plum-blossom needle combined with sulfur ointment and local irradiation for primary cutaneous amyloidosis: a case report].

Zhongguo zhen jiu = Chinese acupuncture &amp; moxibustion
2025

Treatment of primary cutaneous amyloidosis with tofacitinib: preliminary observations from a single-arm clinical trial.

Clinical and experimental dermatology
2025

Familial Primary Cutaneous Amyloidosis Across Generations.

Indian dermatology online journal
2025

Generalized lichen amyloidosis in a pregnant woman: Coincidence or association.

Obstetric medicine
2025

34βE12 is the Most Reliable Marker for Keratin-Derived Cutaneous Amyloid: A Comparative Study.

The American Journal of dermatopathology
2025

Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review.

Frontiers in medicine
2025

The evaluation of Congo red staining combined with fluorescence microscopy in the diagnosis of primary cutaneous amyloidosis.

The Journal of dermatology
2024

Case report: Abrocitinib: a potential therapeutic option for lichen amyloidosis associated with atopic dermatitis.

Frontiers in immunology
2024

[Endogenous skin overloads].

Annales de pathologie
2024

Dermoscopy of Amyloidosis Cutis Dyschromica.

Indian journal of dermatology
2024

Amyloidosis Cutis Dyschromica: A Rare Subtype of Primary Cutaneous Amyloidosis with Dermoscopy.

Indian journal of dermatology
2024

Amyloidoma: A Case Report of Remote Insulin-Derived Amyloidosis in the Setting of Insulin-Dependent Diabetes.

Cureus
2024

[Generalized Amyloid Lichen Associated with Primary Biliary Cholangitis: A Case Report].

Acta gastroenterologica Latinoamericana
2024

Helicobacter pylori associated primary cutaneous nodular amyloidosis improvement through debulking and cauterization.

JAAD case reports
2024

Dermatoscopy of primary localised cutaneous amyloidosis - A cross-sectional study in a setting of South Asian public dermatology department.

Skin health and disease
2023

Characterization of Epidermal Function in Individuals with Primary Cutaneous Amyloidosis.

Clinical, cosmetic and investigational dermatology
2023

Barrier function and ultrastructure characteristics of epidermis in patients with primary cutaneous amyloidosis.

The Journal of dermatology
2023

Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: Four case reports.

World journal of clinical cases
2023

Dupilumab for treatment of severe atopic dermatitis accompanied by lichenoid amyloidosis in adults: Two case reports.

World journal of clinical cases
2023

Immunoglobulin G4-Related Disease-Associated Dermatitis with Pruritus: A Positive Response to Dupilumab.

Life (Basel, Switzerland)
2023

Primary cutaneous amyloidosis: A review of the available studies and gaps in data.

The Australasian journal of dermatology
2022

Amyloidosis Cutis Dyschromica in a 16-Year-Old Filipino Girl: A Case Report.

Dermatopathology (Basel, Switzerland)
2022

Topical halometasone cream combined with fire needle pre-treatment for treatment of primary cutaneous amyloidosis: Two case reports.

World journal of clinical cases
2022

Dermoscopy aids in differentiating primary cutaneous amyloidosis and post-inflammatory hyperpigmentation: A clinico-dermoscopic-histopathaological study.

Journal of cosmetic dermatology
2022

Familial primary cutaneous amyloidosis: Caspase activation may be involved in amyloid formation.

Experimental dermatology
2022

Lichen Amyloidosis on the Scalp: A Case Report.

Clinical, cosmetic and investigational dermatology
2022

Multiple Indolent Asymptomatic Yellow-Orange Patches and Plaques.

Cureus
2022

Diagnosing of primary cutaneous amyloidosis using dermoscopy and reflectance confocal microscopy.

Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
2022

Anosacral amyloidosis in a Chinese-Caribbean male.

JAAD case reports
2022

Tofacitinib for the treatment of primary cutaneous amyloidosis: A case report.

Dermatologic therapy
2021

First Case of Nodular Localized Primary Cutaneous Amyloidosis Treated With Bortezomib and Dexamethasone.

Journal of investigative medicine high impact case reports
2021

Dermoscopic Features of Lichen Amyloidosis in Caucasians-A Case Series and Literature Review.

Medicina (Kaunas, Lithuania)
2021

Amyloidosis cutis dyschromica cases caused by GPNMB mutations with different inheritance patterns.

Journal of dermatological science
2022

Diagnosis of Primary Cutaneous Amyloidosis by Rapid 4,6-Diamidino-2-Phenylindole Staining.

Dermatology (Basel, Switzerland)
2021

Dermoscopic features of primary cutaneous amyloidosis in skin of colour: A retrospective analysis of 48 patients from South India.

The Australasian journal of dermatology
2021

Amyloidosis Cutis Dyschromica, A Rare Subtype of Primary Cutaneous Amyloidosis: Case Report and Literature Review.

Indian dermatology online journal
2021

Primary cutaneous amyloidosis: A clinicopathological, histochemical, and immunohistochemical study.

Indian journal of pathology &amp; microbiology
2021

Fractional Erbium-Doped Yttrium Aluminum Garnet Laser in the Treatment of Primary Cutaneous Amyloidosis.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
2020

Case Report: Diagnosis of Primary Cutaneous Amyloidosis Using Dermoscopy and Reflectance Confocal Microscopy.

Frontiers in medicine
2020

A hyperpigmented plaque in a female patient.

JAAD case reports
2020

Unilateral Isolated Primary Cutaneous Amyloidosis of the External Auditory Canal.

The journal of international advanced otology
2021

Fractional Carbon Dioxide Laser is Effective in Amelioration of Pruritus in Primary Cutaneous Amyloidosis: A Clinical and Biochemical Study.

Lasers in surgery and medicine
2020

Nodular localized primary cutaneous amyloidosis and primary Sjögren's syndrome.

Scandinavian journal of rheumatology
2020

Primary cutaneous amyloidosis of auricular concha.

Indian journal of dermatology, venereology and leprology
2019

Dermoscopy of Primary Cutaneous Amyloidosis in Skin of Color.

Dermatology practical &amp; conceptual
2019

In vivo Diagnosis of Primary Cutaneous Amyloidosis -the Role of Reflectance Confocal Microscopy.

Diagnostics (Basel, Switzerland)
2019

Late-onset amyloidosis cutis dyschromica: an unusual case.

Dermatology online journal
2019

Macular cutaneous amyloidosis treated with methyl aminolevulinate and daylight photodynamic therapy: A case report.

SAGE open medical case reports
2019

Clinicopathological Study of Primary Cutaneous Amyloidosis in a Tertiary Care Center of Eastern India Reveals Insignificant Association with Friction, Scrubbing, and Photo-Exposure: How valid is the "Keratinocyte Hypothesis"?

Indian journal of dermatology
2018

Nodular amyloidosis in a patient with systemic scleroderma.

Dermatology online journal
2018

Atrophic nodular cutaneous amyloidosis.

Anais brasileiros de dermatologia
2017

An unusual presentation of primary cutaneous amyloidosis.

Dermatology online journal
2018

Primary cutaneous amyloidosis associated with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Sjögren syndrome: A case report.

Medicine
2018

Loss of GPNMB Causes Autosomal-Recessive Amyloidosis Cutis Dyschromica in Humans.

American journal of human genetics
2017

Association of amyloidosis cutis dyschromica and familial Mediterranean fever.

Anais brasileiros de dermatologia
2017

Primary cutaneous amyloidosis of the auricular concha - case report.

Anais brasileiros de dermatologia
2017

Primary Cutaneous Amyloidosis: A Clinical, Histopathological and Immunofluorescence Study.

Journal of clinical and diagnostic research : JCDR
2017

Current insight in the localized insulin-derived amyloidosis (LIDA): clinico-pathological characteristics and differential diagnosis.

Pathology, research and practice
2017

Comparative proteomics analysis of primary cutaneous amyloidosis.

Experimental and therapeutic medicine
2017

Amyloidosis Cutis Dyschromica, a Rare Cause of Hyperpigmentation: A New Case and Literature Review.

Pediatrics
2017

Multifocal primary cutaneous nodular amyloidosis.

Dermatology online journal
2017

Successful treatment of lichen amyloidosis accompanied by atopic dermatitis by fractional CO2 laser.

Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
2017

Reflectance confocal microscopy for the characterization of primary cutaneous amyloidosis: a pilot study.

Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
2016

Poikiloderma-like cutaneous amyloidosis--a rare presentation of primary localized cutaneous amyloidosis.

Dermatology online journal
2016

Treatment of primary cutaneous amyloidosis with laser: a review of the literature.

Lasers in medical science
2016

[Primary localized cutaneous nodular amyloidosis: A diagnostic and therapeutic challenge].

Annales de dermatologie et de venereologie
2016

[Primary cutaneous amyloidosis of the external ear: A peculiar, unusual and benign entity].

Medicina clinica
2015

Amyloidosis Cutis Dyschromica: A Rare Reticulate Pigmentary Dermatosis.

Indian journal of dermatology
2015

Efficacy of different modes of fractional CO2 laser in the treatment of primary cutaneous amyloidosis: A randomized clinical trial.

Lasers in surgery and medicine
2016

Amyloidosis cutis dyschromica in two siblings and review of the epidemiology, clinical features and management in 48 cases.

The Australasian journal of dermatology
2015

Health-related quality of life in patients with primary cutaneous amyloidosis.

PloS one
Ver todos os 108 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Amiloidose cutânea.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Amiloidose cutânea

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Symptomatic Vulvar Primary Cutaneous Amyloidosis Associated With Low-Risk HPV: A Case Report.
    Clinical case reports· 2026· PMID 41614014mais citado
  2. Cutaneous Amyloidosis: An Updated Approach Focusing on Macular Amyloidosis.
    Dermatology (Basel, Switzerland)· 2026· PMID 41528921mais citado
  3. Dermatological Manifestations of Amyloid Light-Chain (AL) Amyloidosis: A Case Report Highlighting Early Diagnosis and Treatment.
    Cureus· 2025· PMID 41541959mais citado
  4. [Tapping with plum-blossom needle combined with sulfur ointment and local irradiation for primary cutaneous amyloidosis: a case report].
    Zhongguo zhen jiu = Chinese acupuncture &amp; moxibustion· 2025· PMID 41397731mais citado
  5. Treatment of primary cutaneous amyloidosis with tofacitinib: preliminary observations from a single-arm clinical trial.
    Clinical and experimental dermatology· 2025· PMID 40795212mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:137807(Orphanet)
  2. MONDO:0015301(MONDO)
  3. GARD:132(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q7243115(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Amiloidose cutânea
Compêndio · Raras BR

Amiloidose cutânea

ORPHA:137807 · MONDO:0015301
🇧🇷 Brasil SUS
CEAF
1ATafamidis
Geral
Prevalência
Unknown
Herança
Autosomal dominant, Not applicable
CID-11
Ensaios
2 ativos
Início
All ages
Prevalência
9.8 (Taiwan, Province of China)
MedGen
UMLS
C0268397
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades